Evotec appears to have rebuffed Halozyme’s $2.1 billion acquisition attempt. Elsewhere, Argenx has another blockbuster target ...
AnaptysBio’s drug candidates rosnilimab and ANB032 hold key trial results ahead. Find out why ANAB stock is impacted by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback